Navigation Links
Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
Date:6/1/2009

Panel Discussant Focuses on Longer Duration of Remission among Patients Achieving a Complete Remission with Pixantrone than Complete Remissions Achieved with Standard Chemotherapy

ORLANDO, June 2 /PRNewswire-FirstCall/ -- Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that at the poster and discussion session of the Lymphoma and Plasma Cell Disorders Section at the 2009 American Society of Clinical Oncology ("ASCO") Annual Meeting, new subgroup analysis data were reviewed from the phase III EXTEND (PIX 301) clinical trial of pixantrone (the "PIX 301 EXTEND trial") demonstrating the effectiveness of pixantrone as therapy in patients with aggressive non-Hodgkin's lymphoma ("NHL") for whom anthracycline and related drugs are typically not to be used due to a high risk of cardiac toxicity, including cardiac failure.

Twenty-five of the 70 patients in the PIX 301 EXTEND trial had received prior cumulative doxorubicin doses in excess of the standard 300 mg/m2 associated with six cycles of first line CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) therapy. The median prior exposure of these patients, most of whom had received an anthracycline as part of a salvage regimen, was 386 mg/m2 (with a range of 306 mg/m2 to 778 mg/m2). Following treatment with pixantrone, ten of these 25 patients (40%) achieved a confirmed complete remission ("CR"), unconfirmed remission ("CRu") or partial remission ("PR") (CR=2, CRu= 5, 28%; PR=3, 12%) The lifetime cumulative doxorubicin equivalent dose following pixantrone was 579 mg/m2 (with a range of 361 mg/m2 to 1003 mg/m2). No patient developed a severe reduction (>=20%) in left ventricular ejection fraction (LVEF) and only one patient developed congestive heart failure (CHF). The total cumulative doxorubicin equivalent exposure per treatment cycle for all 68 patients treated with pixantrone is noted in the table below:

           Treatment 
'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
2. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
3. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
4. Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkins Lymphoma Trial
5. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
6. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
7. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
8. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
9. Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
10. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
11. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014   Unique ... Groups Inc.: OTC Pink: UPZS), a Delaware Corporation, ... distribution agreement with Larasan Pharmaceutical Corporation ("Larasan"), a nature-based ... According to the agreement, US-based Larasan will work ... 6" frozen pizza through Larasan,s vast distribution network ...
(Date:7/30/2014)... SANTA CLARA, Calif. , July 30, 2014 /PRNewswire/ ... innovation economy, released a study today that ... venture-backed biopharma and medical device companies.  According to the ... healthcare saw the biggest potential returns since SVB started ... the year of the IPO.  Built on solid healthcare ...
(Date:7/30/2014)... 30, 2014  Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: ... on its expertise in opioid antagonists, announced today ... a prominent international research and development foundation. ... innovative research-based initiatives, including those addressing health issues. ... the delivery of naloxone that could widely expand ...
Breaking Medicine Technology:Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 2Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 3Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 3Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3
... This is your last week to pre-register for MD&M ... of Suppliers ,   Educational Opportunities ... all in   One Convenient Location.     ... at   http://www.MDMEast.com . Medical ...
... May 18, 2012 /PRNewswire-iReach/ -- Denton Vacuum ... today launched a new website that guides ... "The site,s organization and navigation mirror what it,s like ... and understands your business and technical drivers," says Rod ...
Cached Medicine Technology:Medical Device Developers - Network at MD&M East Next Week 2Medical Device Developers - Network at MD&M East Next Week 3Denton Vacuum's New Website Organizes Thin-Film Technology Information By Industry 2
(Date:7/30/2014)... 30, 2014 2014 Deep ... Industry” is a professional and in-depth research ... report provides basic Chitosan information, including Chitosan ... as well as industry overview. This research ... market as well as global industry analysis ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 The report ... Others), by Application (Healthcare, Food, Water Treatment, Pulp & ... & ROW) - Global Trends & Forecasts to 2018". ... size of 229.54 kilotons by 2019, signifying a robust ... study. , Browse 83 market data tables and 33 ...
(Date:7/30/2014)... By Amy Norton ... -- Spending time in a garden might help soothe the ... suggests. Looking at 17 past studies, British researchers found ... garden can help soothe some dementia patients, anxiety. The ... patients are a tough subject to study -- and the ...
(Date:7/30/2014)... Of the many sub-groups of cells jockeying for supremacy ... be those that can proliferate the fastest, researchers at ... an advance online publication of the journal Nature ... treatment of cancer with precision medicines, the study authors ... truly driving the tumor,s growth and metastasis and select ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 According ... and Machine Vision Market by Technology (ICS, MES, ... Embedded), Components (Camera, FGOL), Application (Process, Discrete) - ... published by MarketsandMarkets, the Mexican market is expected ... 6.18% by 2020. , Browse 70 market data ...
Breaking Medicine News(10 mins):Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 2Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 3Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 4Health News:Peracetic Acid Market Worth $664.24 Million by 2018 – New Report by MarketsandMarkets 2Health News:Peracetic Acid Market Worth $664.24 Million by 2018 – New Report by MarketsandMarkets 3Health News:Peracetic Acid Market Worth $664.24 Million by 2018 – New Report by MarketsandMarkets 4Health News:Gardens a Center of Calm for People With Dementia 2Health News:Gardens a Center of Calm for People With Dementia 3Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 2Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 3Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 4
... tool powered by SNAPforSeniors(R) helps members quickly,locate safe housing, ... rash of tornadoes in more than 20 years destroyed ... Tennessee Tuesday night., Emergency warnings gave most residents ... housing, natural disasters bring extra fears. Lack,of mobility, limited ...
... safety review , , FRIDAY, Feb. 8 (HealthDay News) -- ... and severe side effects for others treated for a ... related products. , Most of the children were being ... caused by cerebral palsy, the U.S. Food and Drug ...
... patients (both children and adults) when given gadolinium ... pre-medicated with corticosteroids and antihistamines, according to a ... of Michigan Health Systems in Ann Arbor. ... who have a history of prior allergic-like reaction ...
... Technologically advanced program provides new treatment options for ... patients and physicians throughout the region, WAUKESHA, Wis., Feb. ... opening of its new Center for Advanced Wound,Healing. The hospital ... interested in touring the facility on Wednesday, February 13,from 4:00 ...
... The Integrated,Healthcare Association (IHA) welcomes Leah Binder, ... National Pay for Performance Summit at the,Beverly Hilton ... the,leading forum on pay for performance to enhance ... has made outstanding contributions toward the,improvement of healthcare ...
... the only one if its kind in the Pacific ... Care Alliance (SCCA),and Northwest Hospital & Medical Center today ... the development of a new, state-of-the-art,cancer treatment facility offering ... intention to develop a proton-therapy,facility in September 2006 and ...
Cached Medicine News:Health News:Tennessee Tornadoes Spur Senior Move Managers to Aid Elderly in Crisis 2Health News:Tennessee Tornadoes Spur Senior Move Managers to Aid Elderly in Crisis 3Health News:FDA Warns of Children's Deaths Linked to Botox 2Health News:FDA Warns of Children's Deaths Linked to Botox 3Health News:Allergic-like reactions occur in premedicated patients 2Health News:LifeCare Hospitals of Wisconsin Unveils Center for Advanced Wound Healing 2Health News:Integrated Healthcare Association Welcomes Leah Binder, New CEO of Leapfrog Group to National Pay for Performance Summit 2Health News:Seattle Cancer Care Alliance and Northwest Hospital Sign Letter of Intent to Develop Proton Therapy Center for Cancer Treatment 2Health News:Seattle Cancer Care Alliance and Northwest Hospital Sign Letter of Intent to Develop Proton Therapy Center for Cancer Treatment 3
The OX-2 is configured asstandalone or handheld unit, designed for hospital, transport and home use....
Rad-9™...
... 8600 Series Tabletop/Portable Digital Pulse ... tool for patient monitering. From ... the 8600 has earned the ... and is recognized for its ...
... Medicals ONE™ technology is the ... uses a patented digital sensor ... an analog sensor. Dolphin ONE™ ... the signal in the sensor, ...
Medicine Products: